Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 03, 2015 7:32 AM ET

Biotechnology

Company Overview of Prosensa Holding N.V.

Company Overview

BioMarin Nederland B.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. Its products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. The company develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. It also develops PRO135 that ...

J.H. Oortweg 21

Leiden,  2333 CH

Netherlands

Founded in 1997

Phone:

31 71 332 2100

Fax:

31 71 332 2088

Key Executives for Prosensa Holding N.V.

Chief Executive Officer and Member of Management Board
Age: 56
Co-Founder and Scientific Director
Founder, Chief Development Officer and Member of Scientific & Clinical Advisory Board
Age: 50
Chief Financial Officer, Principal Accounting Officer and Member of Management Board
Age: 55
Chief Business Officer, Senior Vice President of Business Development and Member of Management Board
Age: 40
Compensation as of Fiscal Year 2014.

Prosensa Holding N.V. Key Developments

Prosensa Therapeutics B.V. has Changed its Name to BioMarin Nederland B.V

Prosensa Therapeutics B.V. changed its name to BioMarin Nederland B.V.

Prosensa Holding N.V.(NasdaqGS:RNA) dropped from NASDAQ Composite Index

Prosensa Holding N.V. will be removed from NASDAQ Composite Index.

Prosensa Holding N.V. Announces Advance Liquidation Distribution

Prosensa Holding N.V. announced that based on Asset Sale, the company will make an advance liquidation distribution to its remaining shareholders with each remaining shareholder receiving a cash payment equal to $17.75 per Share as well as one contingent value right to receive cash payments of up to $4.14 per Share in the aggregate upon the achievement of certain product approval milestones, without interest thereon and less any applicable withholding taxes.

Similar Private Companies By Industry

Company Name Region
Mirnext B.V. Europe
Audion Therapeutics BV Europe
SynAffix B.V. Europe
Chiralix BV Europe
Agventure Exploitatie BV Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 24, 2014
--
Private Placement
August 11, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Prosensa Holding N.V., please visit www.prosensa.eu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.